Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Immune system disorders – page 13

  • 1 664 clinical trials
  • 562 recruiting
  • 293 conditions
  • 29 countries

Conditions in this area

293 conditions with trials, the busiest first

Colitis ulcerative120Crohn's disease94Asthma89Dermatitis atopic89HIV infection78Rheumatoid arthritis75Systemic lupus erythematosus63Multiple sclerosis59Psoriasis54Psoriatic arthropathy46Myasthenia gravis44Type 1 diabetes mellitus41Systemic scleroderma40Conjunctivitis allergic34Idiopathic pulmonary fibrosis34Sjogren's syndrome31Cardiac amyloidosis29Interstitial lung disease29Immune thrombocytopenia27Endocrine ophthalmopathy26IgA nephropathy24Vitiligo24Hereditary angioedema22Axial spondyloarthritis21+269

Clinical trials in Immune system disorders

1 664 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 664 clinical trials

Systemic scleroderma+4

Recruiting

A long-term safety study of KYV-101 in patients previously treated for lupus nephritis, systemic sclerosis, myasthenia gravis, rheumatoid arthritis, or stiff person syndrome

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:KYV-101
  • Sponsor:Kyverna Therapeutics Inc.

Systemic scleroderma+5

Recruiting

Using 68Ga-FAPI-46 imaging to detect fibrosis in patients with inflammatory diseases such as Crohn's disease, ulcerative colitis, systemic sclerosis, and lung fibrosis.

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
  • Sponsor:Amsterdam UMC Stichting

Interstitial lung disease+1

Recruiting

A study to evaluate the effectiveness of BI 1015550 in people with lung abnormalities and a family history of pulmonary fibrosis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:BI 1015550
  • Sponsor:Boehringer Ingelheim International GmbH

Renal disorder+1

Recruiting

A study to evaluate the safety of ADX-038 in patients with complement-mediated kidney disease

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:ADX-038
  • Sponsor:Adarx Pharmaceuticals Inc.

Rheumatoid arthritis+1

Recruiting

A study to compare the effectiveness of rituximab and a placebo in patients with interstitial lung disease associated with rheumatoid arthritis

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Vaestra Goetalandsregionen

Hypersensitivity

Recruiting

Standardization of Olea europaea pollen extract for patients with olive pollen allergies

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Sodium Chloride
  • Sponsor:Asac Pharmaceutical Inmunology S.A.

Hereditary angioedema

Recruiting

A study of donidalorsen for children with hereditary angioedema

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Donidalorsen
  • Sponsor:Ionis Pharmaceuticals Inc.

Colitis ulcerative

Recruiting

A study to evaluate the efficacy and safety of etrasimod arginine in children with moderately to severely active ulcerative colitis

InvestigationalNo placebo
Countries:FinlandFinland
  • Participants:0–17 years
  • Substances:Etrasimod Arginine
  • Sponsor:Pfizer Inc.

HIV infection

Recruiting

A study of islatravir and ulonivirine for adults with HIV who have not received previous treatment

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Merck Sharp & Dohme LLC

Myasthenia gravis

Recruiting

A study to evaluate the safety and effectiveness of empasiprubart and efgartigimod alfa in patients with generalized myasthenia gravis.

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Myasthenia gravis

Recruiting

A study of IM-101 in adults with generalized myasthenia gravis or ocular myasthenia gravis

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:IM-101
  • Sponsor:Immunabs Inc.

Autoimmune haemolytic anaemia+1

Recruiting

A study to evaluate the safety and effectiveness of tafasitamab in adults with autoimmune thrombocytopenia or autoimmune hemolytic anemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tafasitamab
  • Sponsor:Incyte Corp.

Substances studied in this area

The therapies tested most often in Immune system disorders trials.

Sodium Chloride61 clinical trialsRituximab50 clinical trialsPrednisone47 clinical trialsAdalimumab40 clinical trialsEmtricitabine40 clinical trialsTenofovir Alafenamide38 clinical trialsTocilizumab38 clinical trialsMethotrexate37 clinical trialsPrednisolone35 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.